Science · Open for opinions
Will Novo Nordisk receive FDA approval for a new obesity or diabetes drug by March 2027?
Novo Nordisk investors expressed disappointment with the company's recent results, raising doubts about the company's pipeline of… 45 opinions, 62% No
- Yes — 38%
- No — 62%
Deadline: March 31, 2027 at 12:00 AM UTC · 45 opinions
Resolution rules
Novo Nordisk investors expressed disappointment with the company's recent results, raising doubts about the company's pipeline of obesity and diabetes drugs.
Source: finance.yahoo.com
Frequently asked questions about this event
How is this event resolved?
Resolução pelo anúncio oficial da FDA (fda.gov) aprovando novo medicamento da Novo Nordisk para obesidade ou diabetes tipo 2 até 31/03/2027. Se nenhuma aprovação for publicada até essa data, resolve 'Não'.
How are points scored?
Points depend on the share of votes your side had when you gave your opinion. Being right earns 100 minus that share. Being wrong costs that share.
Right now No has 62% of the votes: an opinion on it that turns out right earns about 38 points, a wrong one costs about 62.